I nterleukin-21 is a newly described cytokine produced by activated CD4
ϩ T cells and known to mediate its effects through a class I cytokine family receptor, IL-21R. This receptor has homology to the shared ␣-chain of the IL-2 and IL-15 receptors and interacts with the common ␥ cytokine receptor chain (1) . Studies both in humans and mice have shown that IL-21 can enhance the growth and functional activity of T, B, and NK cells (1, 2) . In line with this, enhanced expression of IL-21 and/or IL-21R has been documented in inflammatory diseases (3) (4) (5) . Moreover, mice overexpressing IL-21 exhibit inflammatory infiltrates in several tissues (6) , thus raising the possibility that IL-21 may play an important role in the induction and/or perpetuation of immuneinflammatory processes. In contrast, IL-21 exerts antitumor effects in vivo (1, 7) , suggesting that this cytokine may have therapeutic potential.
Recent studies have led to the identification of a subpopulation of CD4 ϩ CD25 ϩ T lymphocytes, termed regulatory T cells (Treg), 3 that specifically express the forkhead transcription factor, forkhead winged-helix transcription factor gene (Foxp3) (8) . Treg have important effects on the adaptive immune system but in a direction opposing that of IL-21. Indeed, Treg are highly specialized for the suppression of proliferation of autoreactive and effector T cells and therefore in the maintenance of immune homeostasis (8, 9) . This function is further substantiated by the demonstration that the loss of Foxp3 results in a fatal autoimmune disorder (8, 9) . Consistently, a decreased number and/or defective activity of Treg has been documented in autoimmune and allergic diseases (10) . In contrast, Treg may sabotage effective immune responses against microbes and tumors (7, 8) .
In addition to naturally occurring Treg that are produced by the thymus as a functionally distinct and mature population of T cells, Treg can arise in the periphery upon conversion of CD4 ϩ CD25 Ϫ T cells into Foxp3 ϩ CD4 ϩ CD25 ϩ cells in response to a variety of stimuli (8, 11) , thus raising the possibility that the development and/or suppressor activity of Treg can be regulated. Indeed, recent studies have shown that molecules produced by inflammatory and tumor cells can either inhibit or enhance Treg function (12, 13) . As IL-21 and Treg have opposite effects on CD4
ϩ T cell activation, we hypothesized that IL-21 can make conventional CD4 ϩ CD25 Ϫ T cells able to escape Treg-mediated suppression.
Materials and Methods

Cell isolation and culture
Human PBMC were isolated from enriched buffy coats of healthy volunteer donors and used to purify CD4 ϩ T cells with the CD4 multisort magnetic microbeads kit (Miltenyi Biotec). The remaining CD4 Ϫ fraction of PBMC was then used to purify CD8 ϩ T cells by using CD8 multisort magnetic beads (Miltenyi Biotec). Both CD4 ϩ and CD8 ϩ T cells were subsequently fractioned in CD25 ϩ and CD25 Ϫ cells by using CD25 magnetic beads (Miltenyi Biotec). In some experiments, CD3 ϩ T cells were purified from enriched buffy coats using the CD3 magnetic beads (Miltenyi Biotec). Cell purity was routinely evaluated by flow cytometry and ranged between 96 and 98%. The study received approval from the local ethical committee.
Responder 
CFSE labeling
To track the proliferation of responder cells, CD4
ϩ T cells were incubated in 0.2 M CFSE (Invitrogen Life Technologies) at 37°C for 30 min, and CD4 ϩ CD25 ϩ T cells were either left unlabeled or labeled with 2 M PKH26 (Sigma-Aldrich) at room temperature for 3 min and extensively washed before culture. In some experiments, responder cells were labeled with PKH26 and CD4 ϩ CD25 ϩ T cells were labeled with CFSE. CFSE fluorescence was evaluated with the FL1 detector and PKH26 with the FL2 detector. Flow cytometric data were analyzed with the proliferation Wizard module in ModFit LT Macintosh software. The proportion of cells undergoing divisions was determined.
Annexin V (Ann V) staining
To evaluate whether IL-21 affects the survival of CD4 ϩ CD25 ϩ T cells, this cell type was cultured either alone or with CD4 ϩ CD25 Ϫ T cells in the presence of anti-CD3 and/or IL-21. In these cocultures, CD4
ϩ CD25 Ϫ T cells were labeled with CFSE. After 1, 2, 3, and 5 days of culture, the fraction of Ann V ϩ cells was evaluated by flow cytometry using a commercially available kit (Beckman Coulter).
Cell phenotype analysis
Anti-CD4 FITC, anti-CD8 allophycocyanin, anti-CD25 PE (all from Beckman Coulter), anti-CD3 PerCP (BD Biosciences), anti-IL-21R PE (DBA Italia), anti-Foxp3 allophycocyanin (Società Chimici Italiana), and control isotype Abs were used for analysis of relative Ags at the indicated time points according to the manufacturer's instructions.
Cytokine assays
At the end of the cell culture, supernatants were collected and analyzed for the content of IFN-␥ by ELISA using a commercially available kit (R&D Systems).
Statistics
Two-way ANOVA, followed by pairwise multiple comparison procedures (Student-Newman-Keuls method), were performed. Data are expressed as mean Ϯ SEM. ϩ CD25 Ϫ T cell cultures resulted in no change in cell growth (Fig. 1A) . In contrast, IL-21 enhanced the proliferation of anti-CD3-stimulated CD4 ϩ CD25 Ϫ T cells (Fig. 1, A and B) . The IL-21-induced mitogenic effect was dose dependent, with significant proliferation seen at 100 ng/ml IL-21 ( p Ͻ 0.001; Fig. 1A ), a concentration similar to that used by other authors to assess the biological activities of IL-21 in vitro (5 ϩ CD25 Ϫ T cell ratios (i.e., 1:1; p Ͻ 0.05). Although this ratio appears to be unphysiologic, it is noteworthy that only 50% of our CD4 ϩ CD25 ϩ T cells were positive for Foxp3, thus implying that the remaining were indeed activated T cells. Therefore, we used this ratio in the subsequent experiments. Notably, the capacity of IL-21 to counteract the inhibitory effect of CD4 ϩ CD25 ϩ T cells on CD4 ϩ CD25 Ϫ T cell growth was seen independently on the concentration of CD4 ϩ CD25 ϩ T cell used. Consistent with the above data, we also showed that the addition of IL-21 to cocultures of CD4 ϩ CD25 Ϫ and CD4 ϩ CD25 ϩ T cells prevented the inhibition of IFN-␥ secretion (Fig. 1D) .
Results
IL-21 enhances the proliferation of CD4
Analysis of the kinetics of Treg activity in vitro has revealed that murine CD4 ϩ CD25 ϩ T cells mediate their suppressive activity within the first 12 h of T cell activation, and that responding T cells become refractory to suppression if Treg are added 12 h after the activation of target cells (15) . To examine whether this occurs also with human cells, CD4 ϩ CD25 ϩ T cells were added at the same time or 24 h after the activation of CFSE-labeled CD4 ϩ CD25 Ϫ T cells. As expected, CD4 ϩ CD25 ϩ T cells significantly inhibited the proliferation of anti-CD3-stimulated CD4 ϩ CD25 Ϫ T cells when these two cell types were cocultured simultaneously. In contrast, no inhibitory effect was seen when CD4 ϩ CD25 ϩ T cells were added 24 h after the activation of responder cells ( Fig. 2A) . Subsequently, we evaluated whether IL-21 exerts its effects in already established cocultures of responders and Treg. To this end, IL-21 was added 0, 12, 24, and 48 h after the anti-CD3 activation of cocultures of CFSE-labeled CD4 ϩ CD25 Ϫ and CD4 ϩ CD25 ϩ T cells. Data in Fig. 2B show that IL-21 was able to significantly counteract the suppressive effect of 
IL-21 neither diminishes the percentage of Foxp3 ϩ T cells nor directly inhibits the suppressive properties of Treg
The above results suggest different mechanisms by which IL-21 could exert its effects in the cocultures of responder and Treg cells. First, IL-21 could promote Treg apoptosis. Second, IL-21 could directly antagonize the Treg activity. Third, IL-21 could make responder T cells resistant to Treg-mediated suppression. Finally, IL-21 could enable responder cells to resist the antiproliferative activity of Treg, leaving other functions of responder cells compromised. To begin to address this issue, we first assessed which cells express IL-21R. Two-color immunofluorescence revealed that IL-21R expression ranged from 0.5 to 8% in freshly isolated 
CD4
ϩ CD25 ϩ T cells. However, the simultaneous evaluation of Foxp3 and IL-21R in these cells revealed that the receptor was undetectable in freshly isolated Treg (Fig. 3A) . Moreover, IL-21R was barely detectable in CD4 ϩ CD25 Ϫ T cells (Fig. 3A) . We also examined whether IL-21R was differently modulated in cocultures of CD4 ϩ CD25 ϩ and CD4 ϩ CD25 Ϫ T cells. As indicated above, the two cell populations were clearly distinguishable because CD4 ϩ CD25 Ϫ T cells were labeled with CFSE. In anti-CD3-stimulated cocultures, 45 Ϯ 10% of CD4 ϩ CD25 Ϫ and 60 Ϯ 10% of CD4 ϩ CD25 ϩ T cells were positive for IL-21R. The addition of IL-21 to the cocultures did not increase the expression of IL-21R in CD4 ϩ CD25 ϩ T cells (60 Ϯ 5%), although it increased expression in CD4 ϩ CD25 Ϫ T cells (63 Ϯ 7%, p ϭ 0.034). Moreover, CFSE dilutions revealed that proliferating CD4 ϩ CD25 Ϫ T cells in culture with IL-21 expressed the IL-21R (Fig. 3B) .
Subsequently, we examined whether IL-21 affected the survival and/or proliferation of CD4 ϩ CD25 ϩ T cells. To this end, we performed a time-course analysis of Ann V in cocultures of CFSElabeled responders and CD4 ϩ CD25 ϩ T cells stimulated with anti-CD3 in the presence or absence of IL-21. As shown in Fig. 4A, Fig. 5B) .
To assess whether IL-21 suppresses Treg inhibitory functions, CD4 ϩ CD25 T cells were stimulated with anti-CD3 and anti-CD28 in the presence or absence of IL-21. After 5 days, cells were harvested and an aliquot was immediately analyzed for CD25 and Foxp3 by flow cytometry. CD25 expression ranged from 92 to 100% while Foxp3-positive cells were 40 -55%, and these percentages were not changed by IL-21 (93-100% for CD25 and 41-53% for Foxp3). The remaining cells were then tested for their suppressive functions in cocultures with anti-CD3-stimulated CFSE-labeled allogenic CD4 ϩ CD25 Ϫ T cells. As controls, cocultures of CD4 ϩ CD25 Ϫ T cells and allogenic CD4 ϩ CD25 Ϫ T cells or freshly isolated allogenic CD4 ϩ CD25 ϩ T cells (1:1 ratio) were also conducted. Data in Fig. 5C show that freshly isolated CD4 ϩ CD25 ϩ T cells significantly suppressed the anti-CD3-induced proliferation of CD4 ϩ CD25 Ϫ T cells ( p Ͻ 0.05). Similarly, the proliferation of anti-CD3-stimulated CD4 ϩ
CD25
Ϫ T cells was inhibited by CD4 ϩ CD25 ϩ T cells (Treg) induced in vitro by activation of CD4 ϩ CD25 Ϫ T cells with anti-CD3/CD28. This inhibitory effect was seen regardless of whether these cells were induced in the presence or absence of IL-21 ( Fig. 5C ; p Ͻ 0.05).
IL-21 enhances CD8 ϩ T cell growth but does not counteract the Treg-mediated suppression of CD8 ϩ T cell proliferation
Because it is known that Treg abrogate the proliferation of CD8 ϩ T cells (18), we then examined whether IL-21 also counteracts CD4 ϩ CD25 ϩ T cell-mediated inhibition of CD8 ϩ T cell growth. Initially, we evaluated the expression of IL-21R on freshly isolated 
CD8
ϩ T cells. IL-21R was, however, barely detectable on these cells. We also examined whether IL-21R expression on CD8 (Fig. 6B) . However, IL-21 significantly augmented the proliferation of anti-CD3-activated CD8 ϩ CD25 Ϫ T cells at doses of 100 and 200 ng/ml ( Fig. 6B; p Ͻ 0.05) . The addition of CD4 ϩ CD25 ϩ T cells to anti-CD3-activated CD8
ϩ CD25 Ϫ T cell cultures resulted in a marked suppression of CD8 ϩ T cell growth regardless of whether cocultures were performed in the presence or absence of IL-21 (Fig. 6, B and C; p Ͻ 0.05) .
To further confirm these findings, we examined whether IL-21 differently regulates the proliferation of CD8 ϩ and CD4 ϩ T cells when both of these cell types are cocultured with CD4 ϩ CD25 ϩ T cells. To this end, unfractionated, CFSE-labeled, CD3
ϩ T cells were cultured with or without CD4 ϩ CD25 ϩ T cells and stimulated with anti-CD3 in the presence or absence of IL-21. After 5 days of culture, cells were harvested and incubated with a CD8 Ab to discriminate the CD8 and CD4 T cell responses. As shown in Fig.  6D , activation of CD3 ϩ T cells with anti-CD3 significantly increased the percentage of both proliferating CD8 Ϫ and CD8 ϩ T cells (11 Ϯ 3 and 16 Ϯ 3.9%, respectively) in comparison to unstimulated cells (2 Ϯ 0.4 and 1.8 Ϯ 0.6%, respectively; p Ͻ 0.03). Moreover, the addition of IL-21 to such cultures significantly enhanced the growth of both CD8
Ϫ and CD8 ϩ T cells (27 Ϯ 4 and 26 Ϯ 3.9%, p Ͻ 0.05). When anti-CD3-activated CD3 ϩ T cells were cocultured in the presence of CD4 ϩ CD25 ϩ T cells, a marked inhibition in the percentage of proliferating CD8
Ϫ and CD8 ϩ T cells was seen (1.8 Ϯ 0.5 and 7 Ϯ 1%, respectively; p Ͻ 0.01). Notably, the addition of IL-21 to these cocultures significantly blocked the CD4 ϩ CD25 ϩ T cell-mediated suppression of CD8 Ϫ (16 Ϯ 5%; p ϭ 0.04), but not CD8 ϩ T cell growth (9 Ϯ 5%; Fig.  6C ). Overall, these results suggest that IL-21 does not inhibit the intrinsic regulatory capacity of CD4 ϩ CD25 ϩ T cells, but rather makes responding CD4 ϩ T cells resistant to suppression.
IL-21, IL-2, IL-7, and IL-15 differ in their ability to overcome the CD4 ϩ CD25 ϩ T cell-mediated immunosuppression
Studies in other systems have shown that the block of the Treginduced immunosuppression by activating molecules, such as IL-2, IL-7, and IL-15, associates with the ability of these stimuli to reverse the anergic phenotype of suppressors (19, 20) . We therefore compared the effect of IL-21 and the other common ␥-chainrelated cytokines on the proliferation of both CD4 ϩ CD25 Ϫ and CD4 ϩ CD25 ϩ T cells. Freshly isolated CD4 ϩ CD25 Ϫ and CD4 ϩ CD25 ϩ T cells were labeled with CFSE and PKH26, respectively, and then cocultured in medium containing anti-CD3 in the presence or absence of IL-21 (100 ng/ml), IL-2 (100 ng/ml), IL-7 (100 ng/ml), or IL-15 (100 ng/ml) for 5 days. Data in Fig. 7A show that all of these cytokines were effective in counteracting the CD4 ϩ CD25 ϩ T cell-mediated suppression of anti-CD3-activated CD4 ϩ CD25 Ϫ T cells ( p Ͻ 0.01), even though the proliferative effect of IL-2, IL-7, and IL-15 on CD4 ϩ CD25 Ϫ T cells was more marked than that of IL-21. By contrast, in the same cell cultures, IL-2, IL-7, and IL-15, but not IL-21 significantly enhanced the growth of CD4 ϩ CD25 ϩ T cells ( Fig. 7B ; p Ͻ 0.001). The representative experiment depicted in Fig. 7C ϩ CD25 Ϫ T cell proliferation (Fig. 7D) .
Discussion
This study was undertaken to examine whether the recently described T cell-derived cytokine IL-21 is able to overcome Tregmediated immunosuppression. Indeed, recent studies have shown that high IL-21 levels occur in inflammatory diseases that have been associated with a defective capacity of counterregulatory mechanisms to dampen T cell-mediated inflammatory diseases (3-5). ϩ CD25 ϩ T cell growth in accordance with previously published data (18 -21) . In this context, it is also noteworthy that in the absence of CD4 ϩ CD25 Ϫ T cells, that are known to be an important source of IL-2, almost all of the CD4 ϩ CD25 ϩ T cells underwent apoptosis by 24 h of culture with anti-CD3 ϩ IL-21, clearly indicating that IL-21 is not a survival factor for Treg. These data, along with the demonstration that, in other cell systems, IL-2 and IL-4, but not IL-13, are growth factors for Treg (11, 23) , suggest that signaling through the common ␥-chain that is shared by all of these cytokines is not sufficient for maintaining/prolonging CD4 ϩ CD25 ϩ T cell survival. In line with previously published studies, we demonstrate that IL-21 is an important growth factor for both CD4 ϩ CD25 Ϫ and CD8 ϩ CD25 Ϫ T cells (1), thus emphasizing the possible contribution of IL-21 to immune-mediated diseases. Indeed, we recently showed that IL-21 is produced in excess in the inflamed gut of patients with inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and that IL-21 helps sustain the ongoing Th1 cell response in the gut of patients with Crohn's disease (3) . Moreover, enhanced expression of IL-21 and IL-21R has been described in patients with systemic sclerosis (4), and up-regulation of IL-21R also occurs in synovial macrophages and fibroblasts of patients with rheumatoid arthritis (24) . Studies in experimental models of autoimmune diseases have also shown that administration of IL-21 into mice enhances the recruitment of leukocytes into inflamed tissues and increases the severity of the inflammation (25) . Finally, increased production of IL-21 has been described in NOD mice that are known to develop diabetes due to ␤ cell destruction by activated T cells (26) . Overall, these findings suggest that IL-21 may activate the autoreactive T cell repertoire and trigger the effector phase of immune-mediated diseases. These effects could be also facilitated by the ability of IL-21 to counteract the suppressor function of Treg.
Since their discovery, Treg have been found to play important roles in the control of immune responses. Although they were initially described to modulate self-tolerance and to protect against autoimmunity, more recent studies have suggested that Treg may also be implicated in suppressing immune responses in infective and neoplastic diseases (7, 10) . Concomitantly, several authors have shown that Treg activity can be differently modulated by inflammatory molecules, bacterial products, and tumor-derived molecules, thus raising the possibility that we can either enhance or inhibit Treg function for therapeutic purposes. In this context, our data suggest that manipulation of IL-21 activity may be a promising way to differently regulate the effect of Treg on immune cells. Therefore, in immunoinflammatory disorders in which high IL-21 associates with defective Treg function, blocking IL-21 may not only decrease bystander T cell activation, but also reconstitute the suppressor function of Treg, thus leading to the resolution of ongoing inflammatory processes. In contrast, in circumstances in which the Treg response could be detrimental rather than protective for the host, such as during viral infections and malignancies (27) , administration of IL-21 could antagonize Treg, thereby contributing to relieve the virus-or tumor-induced Treg-mediated immunosuppression.
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